Technical Analysis for CNCE - Concert Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 4.45 4.95% 0.21
CNCE closed up 4.95 percent on Thursday, April 22, 2021, on 87 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Flat
Historical CNCE trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 4.95%
Narrow Range Bar Range Contraction 4.95%
Oversold Stochastic Weakness 4.95%
New 52 Week Closing Low Bearish 6.21%
Narrow Range Bar Range Contraction 6.21%
NR7 Range Contraction 6.21%
New 52 Week Low Weakness 6.21%
Down 3 Days in a Row Weakness 6.21%
Older End-of-Day Signals for CNCE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 5 hours ago
20 DMA Resistance about 7 hours ago
Up 10% about 7 hours ago
Up 1 ATR about 7 hours ago
60 Minute Opening Range Breakout about 8 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Concert Pharmaceuticals, Inc., a biotechnology company, develops drug candidates. Its drug candidates address various therapeutic areas, including hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, schizophrenia, multiple tumors, and hyperparathyroidism, as well as provide agents for diabetic nephropathy and other forms of chronic kidney diseases. The company also develops CTP-354, a GABA(A) receptor subtype-selective modulator for the treatment of spasticity and chronic pain. Concert Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline plc and Celgene Corporation. The company was founded in 2006 and is based in Lexington, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Life Sciences Pain Flash Schizophrenia Kidney Disease Spas Thyroid Chronic Pain Tumors Summit Chronic Kidney Disease HIV Kidney Diseases Glaxosmithkline Neuropathic Pain Diabetic Nephropathy Bristol Myers Squibb Hot Flash Hyperparathyroidism Spasticity Chronic Kidney Diseases

Is CNCE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.5
52 Week Low 4.11
Average Volume 361,198
200-Day Moving Average 9.42
50-Day Moving Average 5.82
20-Day Moving Average 4.70
10-Day Moving Average 4.46
Average True Range 0.32
ADX 46.54
+DI 21.42
-DI 29.22
Chandelier Exit (Long, 3 ATRs ) 5.07
Chandelier Exit (Short, 3 ATRs ) 5.06
Upper Bollinger Band 5.29
Lower Bollinger Band 4.11
Percent B (%b) 0.29
BandWidth 25.13
MACD Line -0.48
MACD Signal Line -0.52
MACD Histogram 0.0422
Fundamentals Value
Market Cap 136.39 Million
Num Shares 30.6 Million
EPS -3.35
Price-to-Earnings (P/E) Ratio -1.33
Price-to-Sales 41.69
Price-to-Book 2.72
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.21
Resistance 3 (R3) 5.22 4.98 5.08
Resistance 2 (R2) 4.98 4.79 4.97 5.04
Resistance 1 (R1) 4.72 4.67 4.85 4.70 5.00
Pivot Point 4.48 4.48 4.54 4.47 4.48
Support 1 (S1) 4.21 4.28 4.34 4.20 3.90
Support 2 (S2) 3.97 4.16 3.96 3.86
Support 3 (S3) 3.71 3.97 3.82
Support 4 (S4) 3.69